{"id":957542,"date":"2026-05-04T08:41:35","date_gmt":"2026-05-04T12:41:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/"},"modified":"2026-05-04T08:41:35","modified_gmt":"2026-05-04T12:41:35","slug":"fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/","title":{"rendered":"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial"},"content":{"rendered":"
\n

HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (\u201cFibroBiologics\u201d), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the first batch of its CYWC628 drug product to support its Phase 1\/2 clinical trial in patients with diabetic foot ulcers (DFUs).<\/p>\n

The CYWC628 drug product was manufactured in accordance with the U.S. Food and Drug Administration\u2019s current Good Manufacturing Practices (cGMP) and has successfully passed all required safety and quality testing, enabling its release for clinical use. This milestone follows the Company\u2019s recent completion of manufacturing of the first cGMP batch of CYWC628.<\/p>\n

CYWC628 is an investigational fibroblast-based therapy designed to address DFUs, a chronic condition affecting millions of patients worldwide with limited effective long-term treatment options.<\/p>\n

The Phase 1\/2 clinical trial is evaluating the safety, tolerability, and preliminary efficacy of CYWC628 in patients with DFUs.<\/p>\n

\u201cWith the first batch of the CYWC628 drug product released, we are now positioned to begin enrolling patients in our Phase 1\/2 DFU trial,\u201d said Pete O\u2019Heeron, Founder and CEO of FibroBiologics. \u201cThis milestone allows us to begin the process of generating the data needed to evaluate safety, tolerability, and efficacy in DFUs. These initial results will be important in shaping the commercial path forward for CYWC628 and further validating our fibroblast-based platform.\u201d<\/p>\n

For more information, please visit FibroBiologics\u2019\u00a0website<\/a>\u00a0or email FibroBiologics at\u00a0info@fibrobiologics.com<\/a>.\u00a0\u00a0<\/p>\n

\n Cautionary Statement Regarding Forward-Looking Statements\u00a0<\/strong>\n <\/p>\n

This communication\u00a0contains\u00a0“forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning indications of interest, plans for, and the anticipated timing of the initiation\u00a0and completion\u00a0of, FibroBiologics\u2019 clinical trials, and the robustness, progress, timing, and momentum of FibroBiologics\u2019 research and development program. These forward-looking statements are based on FibroBiologics’ management’s current expectations, estimates, projections, and beliefs, as well as a number of assumptions concerning future events. When used in this communication, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative\u00a0versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics’ management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption “Risk Factors” and elsewhere in FibroBiologics’ annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC’s website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics’ liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics\u2019 R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; (d) the ability of FibroBiologics to successfully prosecute its patent applications;\u00a0(e) FibroBiologics\u2019 ability to\u00a0manufacture its product candidates; and (f) FibroBiologics\u2019 ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether\u00a0as a result of\u00a0new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.\u00a0<\/p>\n

\n About FibroBiologics<\/strong>\n <\/p>\n

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents\/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration.\u00a0For more information, visit\u00a0www.FibroBiologics.com<\/a>.<\/p>\n

\n General Inquiries:<\/strong>
\n
\n info@fibrobiologics.com<\/a>\n <\/p>\n

\n Investor Relations:<\/strong>
\n
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (\u201cFibroBiologics\u201d), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the first batch of its CYWC628 drug product to support its Phase 1\/2 clinical trial in patients with diabetic foot ulcers (DFUs). The CYWC628 drug product was manufactured in accordance with the U.S. Food and Drug Administration\u2019s current Good Manufacturing Practices (cGMP) and has successfully passed all required safety and quality testing, enabling its release for clinical use. This milestone follows the Company\u2019s recent completion of manufacturing of the first cGMP batch of CYWC628. … <\/p>\n

Continue reading “FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-957542","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (\u201cFibroBiologics\u201d), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the first batch of its CYWC628 drug product to support its Phase 1\/2 clinical trial in patients with diabetic foot ulcers (DFUs). The CYWC628 drug product was manufactured in accordance with the U.S. Food and Drug Administration\u2019s current Good Manufacturing Practices (cGMP) and has successfully passed all required safety and quality testing, enabling its release for clinical use. This milestone follows the Company\u2019s recent completion of manufacturing of the first cGMP batch of CYWC628. … Continue reading "FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-04T12:41:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTc0NiM3NTc5MjM2IzIyNjM1MzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\\\/2 Diabetic Foot Ulcer Clinical Trial\",\"datePublished\":\"2026-05-04T12:41:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/\"},\"wordCount\":742,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTc0NiM3NTc5MjM2IzIyNjM1MzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/\",\"name\":\"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\\\/2 Diabetic Foot Ulcer Clinical Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTc0NiM3NTc5MjM2IzIyNjM1MzE=\",\"datePublished\":\"2026-05-04T12:41:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTc0NiM3NTc5MjM2IzIyNjM1MzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTc0NiM3NTc5MjM2IzIyNjM1MzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\\\/2 Diabetic Foot Ulcer Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial - Market Newsdesk","og_description":"HOUSTON, May 04, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (\u201cFibroBiologics\u201d), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the first batch of its CYWC628 drug product to support its Phase 1\/2 clinical trial in patients with diabetic foot ulcers (DFUs). The CYWC628 drug product was manufactured in accordance with the U.S. Food and Drug Administration\u2019s current Good Manufacturing Practices (cGMP) and has successfully passed all required safety and quality testing, enabling its release for clinical use. This milestone follows the Company\u2019s recent completion of manufacturing of the first cGMP batch of CYWC628. … Continue reading \"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-04T12:41:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTc0NiM3NTc5MjM2IzIyNjM1MzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial","datePublished":"2026-05-04T12:41:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/"},"wordCount":742,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTc0NiM3NTc5MjM2IzIyNjM1MzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/","name":"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTc0NiM3NTc5MjM2IzIyNjM1MzE=","datePublished":"2026-05-04T12:41:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTc0NiM3NTc5MjM2IzIyNjM1MzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTc0NiM3NTc5MjM2IzIyNjM1MzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ulcer-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1\/2 Diabetic Foot Ulcer Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957542","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=957542"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957542\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=957542"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=957542"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=957542"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}